{"id":"W2013246214","doi":"10.1159/000048240","title":"Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial","year":2002,"lang":"en","type":"article","venue":"Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada); University of Toronto; Mount Sinai Hospital","funders":"Eli Lilly and Company","keywords":"Medicine; Gemcitabine; Neutropenia; Nausea; Metastatic breast cancer; Chemotherapy; Internal medicine; Surgery; Phases of clinical research; Performance status; Breast cancer; Cancer; Vomiting; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009796115,0.0008022953,0.00137695,0.0002586744,0.0002487345,0.00076558,0.000523471,0.001176776,0.002659955],"category_scores_gemma":[0.0006669311,0.0002417499,0.0007386467,0.0003602962,0.0003584683,0.0003666243,0.0002335031,0.002120925,0.0004584383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005780937,"about_ca_system_score_gemma":0.0009545584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004237575,"about_ca_topic_score_gemma":0.001479669,"domain_scores_codex":[0.9997676,0.0001373889,0.00001381259,0.00002931604,0.00001965121,0.00003224475],"domain_scores_gemma":[0.9995634,0.0000914912,0.00009909346,0.00001853306,0.00001752552,0.0002099428],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6877965,0.03327747,0.0117543,0.003583043,0.002353929,0.0007218407,0.0002460581,0.004104285,0.02390259,0.0002840621,0.007704328,0.2242717],"study_design_scores_gemma":[0.7942992,0.1837522,0.01140557,0.0001967269,0.0007187555,0.0005682815,0.00003474986,0.001635796,0.002504366,0.000135074,0.004726335,0.00002287341],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9770284,0.01697995,0.0003805655,0.0009867451,0.0002218759,0.00168582,0.0006911791,0.00008805519,0.00193734],"genre_scores_gemma":[0.978614,0.01211115,0.001469923,0.001457661,0.0003575121,0.002219366,0.001814136,0.00002029253,0.001935835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002659955,"threshold_uncertainty_score":0.008898437,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04271448628610791,"score_gpt":0.3772395463558425,"score_spread":0.3345250600697346,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}